A Phase I Study to Investigate the Tolerability and Safety of ONO-4685 Given as Monotherapy in T Cell Lymphoma and CLL/SLL
A Phase I Study to Investigate the Tolerability and Safety of ONO-4685 Given as Monotherapy in T Cell Lymphoma and CLL/SLL
Relapsed or Refractory T Cell Lymphoma and Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
DRUG: ONO-4685
Dose-limiting toxicities(DLT), Up to 3 Weeks|Incidence and severity of AEs and SAEs, Through study completion, an average of 1 year|Laboratory abnormality profile of ONO-4685 as measured by incidence and severity of clinical laboratory abnormalities, Through study completion, an average of 1 year|Body temperature, Through study completion, an average of 1 year|Pulse rate, Through study completion, an average of 1 year|Systolic/diastolic blood pressure, Through study completion, an average of 1 year|Change of weight during the trial period, Through study completion, an average of 1 year|Chest X-ray test, Through study completion, an average of 1 year|ECG parameters by 12 lead ECG(pulse rate), Through study completion, an average of 1 year|ECG parameters by 12 lead ECG(RR), Through study completion, an average of 1 year|ECG parameters by 12 lead ECG(QT interval), Through study completion, an average of 1 year|ECG parameters by 12 lead ECG(corrected QT intervals [QTcF, QTcB]), Through study completion, an average of 1 year|ECG parameters by 12 lead ECG(PR interval), Through study completion, an average of 1 year|ECG parameters by 12 lead ECG(QRS), Through study completion, an average of 1 year
Best overall response (BOR), Through study completion, an average of 1 year|Overall response rate (ORR), Through study completion, an average of 1 year|Complete response rate (CRR), Through study completion, an average of 1 year|Duration of response (DOR), Through study completion, an average of 1 year|Progression Free Survival(PFS), Through study completion, an average of 1 year|Time to response (TTR), Through study completion, an average of 1 year|Overall Survival(OS), Through study completion, an average of 1 year|The percent change of tumor volume, Through study completion, an average of 1 year|Pharmacokinetics(Cmax), Through study completion, an average of 1 year|Pharmacokinetics(Tmax), Through study completion, an average of 1 year|Pharmacokinetics(AUC), Through study completion, an average of 1 year|Pharmacokinetics(Ceoi), Through study completion, an average of 1 year|Pharmacokinetics(T1/2), Through study completion, an average of 1 year|Pharmacokinetics(Ctrough), Through study completion, an average of 1 year|Volume of distribution(Vd), Through study completion, an average of 1 year|clearance(CL), Through study completion, an average of 1 year|Anti-ONO-4685 antibody, Through study completion, an average of 1 year
A Phase I Study to Investigate the Tolerability and Safety of ONO-4685 Given as Monotherapy in T Cell Lymphoma and CLL/SLL